NCT06064279View on ClinicalTrials.gov

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 4, 2024

Primary Completion Date

June 4, 2024

Study Completion Date

June 4, 2024

Conditions
Stage IV NSCLC
Interventions
DRUG

Poly ICLC

Tol like receptor 3 agonist

DRUG

IVIG

pooled IVIG

Trial Locations (1)

77030-4211

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

Sponsors

Collaborators (1)

Oncovir, Inc.
All Listed Sponsors
collaborator

Oncovir, Inc.

INDUSTRY

lead

VA Office of Research and Development

FED

NCT06064279 - Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC | Biotech Hunter | Biotech Hunter